• Seelos Announces Patent for SLS-007 americanpharmaceuticalreview
    November 02, 2020
    Seelos Therapeutics has been issued U.S. patent number 10815271 (application number 16/311,593) from the United States Patent and Trademark Office (USPTO) covering the composition of matter for SLS-007.
  • Seelos Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease americanpharmaceuticalreview
    July 03, 2020
    Seelos Therapeutics announced the initiation of a preclinical study of SLS-007 in Parkinson's disease (PD) delivered through an adeno associated viral (AAV) vector targeting the non-amyloid component core (NACore) of alpha synuclein (α-synuclein).
PharmaSources Customer Service